PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells Corrigendum in /10.3892/etm.2024.12399

Chen,Chen; Yang,Dinghua; Zeng,Qinghua; Luo,Liang; Cai,Chengzhi

doi:10.3892/etm.2018.5967

PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells

Corrigendum in: /10.3892/etm.2024.12399

Authors:
- Chen Chen
- Dinghua Yang
- Qinghua Zeng
- Liang Luo
- Chengzhi Cai
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, Changsha, Hunan 410002, P.R. China, Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Rheumatology and Immunology, Hunan Provincial People's Hospital, Changsha, Hunan 410002, P.R. China
Published online on: March 20, 2018 https://doi.org/10.3892/etm.2018.5967
Pages: 4543-4549

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor with high incidence and an average age of onset of 50-70 years old. However, at present there is no effective treatment for this disease. The aim of the present study was to investigate the effects of a c‑Met inhibitor, PF‑2341066 and a cyclooxygenase‑2 (COX‑2) inhibitor, celecoxib, on c‑Met and COX‑2 expression, proliferation and apoptosis. The results demonstrated that c‑Met and COX‑2 are highly expressed in hepatobiliary calculus with cholangiocarcinoma. PF‑2341066 was able to downregulate the expression of c‑Met and COX‑2 in a dose‑dependent manner at the mRNA and protein levels in human cholangiocarcinoma QBC939 cells. Furthermore, combined treatment with PF‑2341066 with celecoxib downregulated the mRNA expression of both genes, inhibited cell proliferation and promoted cell apoptosis. It was also demonstrated that PF‑2341066 and celecoxib treatment was able to restrict the expression of vascular endothelial growth factor (VEGF). The results of the present study suggest that PF‑2341066 and celecoxib may inhibit the development of cholangiocarcinoma by downregulating the expression of c‑Met and COX‑2 to inhibit cell proliferation, promote apoptosis and prevent VEGF‑mediated tumor angiogenesis. Co‑treatment with PF‑2341066 and celecoxib may be a potential therapeutic strategy for hepatobiliary calculus with cholangiocarcinoma.

View Figures

View References

1	Haga H, Yan IK, Takahashi K, Wood J, Zubair A and Patel T: Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. J Extracell Vesicles. 4:249002015. View Article : Google Scholar : PubMed/NCBI
2	Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K and Nakamura T: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 53:35–69. 2005. View Article : Google Scholar : PubMed/NCBI
3	Sandler AB and Dubinett SM: COX-2 inhibition and lung cancer. Semin Oncol. 31 2 Suppl 7:S45–S52. 2004. View Article : Google Scholar
4	Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, et al: An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67:4408–4417. 2007. View Article : Google Scholar : PubMed/NCBI
5	Socoteanu MP, Mott F, Alpini G and Frankel AE: c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14:2990–2994. 2008. View Article : Google Scholar : PubMed/NCBI
6	Gandou C, Harada K, Sato Y, Igarashi S, Sasaki M, Ikeda H and Nakanuma Y: Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Hum Pathol. 44:811–821. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, et al: A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clin Cancer Res. 20:5796–5807. 2014. View Article : Google Scholar : PubMed/NCBI
8	Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE and Sckell A: The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: An intravital microscopy study in mice. BMC Cancer. 6:92006. View Article : Google Scholar : PubMed/NCBI
9	Zhou YY, Hu ZG, Zeng FJ and Han J: Clinical profile of cyclooxygenase-2 inhibitors in treating non-small cell lung cancer: A meta-analysis of nine randomized clinical trials. PLoS One. 11:e01519392016. View Article : Google Scholar : PubMed/NCBI
10	Clapéron A, Mergey M, Nguyen Ho-Bouldoires TH, Vignjevic D, Wendum D, Chrétien Y, Merabtene F, Frazao A, Paradis V, Housset C, et al: EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J Hepatol. 61:325–332. 2014. View Article : Google Scholar : PubMed/NCBI
11	Hung TH, Li YH, Tseng CP, Lan YW, Hsu SC, Chen YH, Huang TT, Lai HC, Chen CM, Choo KB and Chong KY: Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines. Cancer Gene Ther. 22:262–270. 2015. View Article : Google Scholar : PubMed/NCBI
12	Marti P, Stein C, Blumer T, Abraham Y, Dill MT, Pikiolek M, Orsini V, Jurisic G, Megel P, Makowska Z, et al: YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology. 62:1497–1510. 2015. View Article : Google Scholar : PubMed/NCBI
13	Kang YK, Muro K, Ryu MH, Yasui H, Nishina T, Ryoo BY, Kamiya Y, Akinaga S and Boku N: A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs. 32:355–361. 2014. View Article : Google Scholar : PubMed/NCBI
14	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
15	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
16	Rizvi S and Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
17	Patel MB, Pothula SP, Xu Z, Lee AK, Goldstein D, Pirola RC, Apte MV and Wilson JS: The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: Antiangiogenic implications in pancreatic cancer. Carcinogenesis. 35:1891–1900. 2014. View Article : Google Scholar : PubMed/NCBI
18	Park HJ, Kim K, Paik JH, Chie EK, Kim S, Jang JY, Kim SW, Han SW, Oh DY, Im SA, et al: Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy? Clin Transl Oncol. 18:625–631. 2016. View Article : Google Scholar : PubMed/NCBI
19	Wu GS, Zou SQ, Liu ZR, Tang ZH and Wang JH: Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol. 9:1302–1306. 2003. View Article : Google Scholar : PubMed/NCBI
20	Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y and Ochiai A: Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 30:73–81. 2000. View Article : Google Scholar : PubMed/NCBI
21	Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 89:2637–2645. 2000. View Article : Google Scholar : PubMed/NCBI
22	Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
23	Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997. View Article : Google Scholar : PubMed/NCBI
24	Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi T: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:3761–3764. 1998.PubMed/NCBI
25	Ristimäki A, Honkanen N, Jänkälä H, Sipponen P and Härkönen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1276–1280. 1997.PubMed/NCBI
26	Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schrör K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:198–204. 1999.PubMed/NCBI
27	Alshafie GA, Abou-Issa HM, Seibert K and Harris RE: Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep. 7:1377–1381. 2000.PubMed/NCBI
28	Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:625–631. 2002.PubMed/NCBI
29	Balansky R, Ganchev G, Iltcheva M, Nikolov M, La Maestra S, Micale RT, D'Agostini F, Steele VE and De Flora S: Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke. Curr Cancer Drug Targets. 15:188–195. 2015. View Article : Google Scholar : PubMed/NCBI
30	Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, Symes J and Isner JM: Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol. 150:1673–1685. 1997.PubMed/NCBI
31	Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
32	Lee SH, Jeong D, Han YS and Baek MJ: Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 89:1–8. 2015. View Article : Google Scholar : PubMed/NCBI